PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.201
https://www.valueinhealthjournal.com/article/S1098-3015(20)32457-8/fulltext
Title :
PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32457-8&doi=10.1016/j.jval.2020.08.201
First page :
Section Title :
Open access? :
No
Section Order :
10157